Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Divided Dose of TRAVATAN®
NCT01298687Phase 2Completed
- Sponsor
- Alcon Inc.
- Start
- Feb 2011
- Primary completion
- Apr 2011
- Modality
- Prodrugs/Conditional Activator Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of travoprost in open-angle glaucoma (OAG) and ocular hypertension (6 arms), sponsored by Alcon Inc. Primary endpoint: 24-hour Area Under the Curve (AUC) in IOP Reduction at Day 5. Started Feb 2011; status: completed.
02
Drugs
travoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT01298687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01298687.